系统性红斑狼疮的新型治疗方法：免疫抑制剂。

Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents.

作者信息

Dooley Mary Anne, Ginzler Ellen M

出版信息

Rheum Dis Clin North Am. 2006 Feb;32(1):91-102, ix. doi: 10.1016/j.rdc.2005.11.003.

DOI:10.1016/j.rdc.2005.11.003

Abstract

There has been unprecedented growth in new therapeutic approaches for the treatment of systemic lupus erythematosus (SLE). These approaches include re-evaluation of the doses and duration of therapy with traditional agents, including intravenous cyclophosphamide and azathioprine. Drugs that were developed for other uses are being applied to specific SLE manifestations, and have spurred larger scale trials for overall disease activity. In addition, several new agents show promise in clinical trials; many have safer toxicity profiles than do traditional therapies. Some of these agents have multiple immunomodulatory effects, whereas others interfere with a specific immunologic process in one of the pathogenetic pathways of SLE activity.

摘要

系统性红斑狼疮（SLE）治疗的新疗法取得了前所未有的发展。这些方法包括重新评估传统药物（如静脉注射环磷酰胺和硫唑嘌呤）的治疗剂量和疗程。一些原本用于其他用途的药物正被应用于SLE的特定表现，并促使针对整体疾病活动进行更大规模的试验。此外，几种新药在临床试验中显示出前景；许多药物的毒性特征比传统疗法更安全。其中一些药物具有多种免疫调节作用，而其他药物则干扰SLE活动发病机制途径之一中的特定免疫过程。